Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.56 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.56 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6762449 | 0.99 | ESR1 (0.54) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL6763968 | 0.97 | ESR1 (0.52) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL6761343 | 0.96 | ESR1 (0.52) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL6759835 | 0.96 | ESR1 (0.54) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL6761384 | 0.95 | ESR1 (0.49) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL6759786 | 0.93 | ESR1 (0.47) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL6761242 | 0.93 | ESR1 (0.54) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL6762899 | 0.92 | ESR1 (0.54) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL6761448 | 0.90 | ESR1 (0.46) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL6761221 | 0.89 | ESR1 (0.47) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040247698-A1 | Erectile Dysfunction Treatment | VALENZUELA CORTES CARMEN MARIA (CL) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040247698-A1 | Erectile Dysfunction Treatment | PDE3A, PDE3B, PDE12 | ESR1 189/4885AKR1C4 2439/4885AKR1C3 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.